ACONW experienced a dramatic transformation with cash surging from $454K to $12.0M (+2,549%) while outstanding shares quadrupled from 582K to 2.3M shares, indicating a major equity financing event.
The massive increase in cash and shares outstanding suggests ACONW completed a significant equity raise, providing substantial liquidity but likely at considerable dilution to existing shareholders. This capital infusion should address near-term funding needs for this medical technology company, though operating losses deepened to $7.2M.
ACONW's financial profile was completely transformed through what appears to be a major equity financing, with cash increasing 25x to $12.0M and total assets growing 544% to $13.7M. While the company raised substantial capital, operating cash flow losses worsened from -$5.3M to -$7.2M, though operational metrics showed modest improvement with revenue up 66% to $76K and the company achieving gross profitability. The dramatic improvement in the balance sheet provides significant runway, but the deteriorating cash burn rate and minimal revenue base remain concerns for this early-stage medical device company.
Cash position surged 2548.6% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 1403.9% — improving short-term liquidity or inventory/receivables build.
Equity base grew 1223.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 543.9% — expansion through organic growth, acquisitions, or capital deployment.
Capital expenditure jumped 320.9% — major investment cycle underway; assess returns on deployment.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Strong top-line growth of 65.6% — accelerating demand or successful expansion into new markets.
Receivables surged 62% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Operating cash flow fell 35.9% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →